Nordion Inc. (NDZ) - Overbought - views

Nordion Inc. has hit a technical signal on 3 different technical indicators. NDZ is in the Capital Goods sector. The technical signals indicate that the stock is Overbought right now. The 3 indicators: Commodity Channel Index, Relative Strength Index and the Fast Stochastics were all triggered based on the last closing price of $10.08 on Feb 3.

There are currently 6 analysts covering the company. Of these analysts, 4 have a buy recommendation. The current consensus estimate for quarterly earnings among the 6 analysts covering the stock is $0.17 per share. Last quarter the company earned $0.10 per share. The consensus estimate for this years earnings is $0.72 per share as compared to the next years' expectation, of $0.72 per share. The consensus estimate for next years earnings is $0.72 per share, which represents forecast growth of 0.0%.

Over the last 52 weeks, the stock has been trading between $8.00 and $12.28. More recently in the last 4 weeks, the stock has been trading between $8.38 and $10.12. Yesterday the stock traded between $9.95 and $10.12. The stock currently has a PE ratio of 23.4.

Nordion Inc. is trading 9.2% from its 20-day simple moving average (SMA) of $9.23 and 13.3% from its 50-day SMA and 5.61% from its 200-day SMA. Average daily volume over the last 30 days has been 228,491 shares.

At yesterdays close: the RSI was at 80.1, the CCI was at 152.2 and the Fast Stochastic was at 96.9. NDZ closed yesterday at $10.08, on volume of 498,328 shares as compared to an average volume of 228,491 over the last 4 weeks.

Nordion Inc., a health science company, provides various products and services used for the prevention, diagnosis, and treatment of diseases worldwide. It is involved in the processing, packaging, and delivery of medical isotopes used in the diagnosis and treatment of diseases, such as cardiology, oncology, and neurology. The company primarily offers Molybdenum-99, which decays into Technetium-99, utilized in nuclear medical procedures; processes and sells other reactor isotopes, including Xe-133 used in lung scans and I-125 used to treat prostate cancer, as well as I-131 used to treat hyperthyroidism, thyroid cancer, and non-Hodgkin's lymphoma; and manufactures and processes cyclotron isotopes. It also supplies targeted therapies for various cancers, which focus on targeting the disease from within the body with a higher concentration of radiation directed to the tumor. Its primary targeted therapies product includes TheraSphere, a treatment for inoperable primary and metastatic liver cancer, as well as offers radiopharmaceutical and medical imaging services; and contract manufacturing services for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development. In addition, the company provides gamma sterilization technologies used to sterilize disposable medical devices and supplies, such as surgeon's gloves, syringes, sutures, and catheters, as well as pharmaceuticals; and used for the treatment of food and consumer products. It produces and installs Cobalt-60 irradiation sources; and designs, constructs, installs, and maintains commercial gamma sterilization systems. Nordion Inc. offers its products and services to pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics, and research laboratories. The company was formerly known as MDS Inc. and changed its name to Nordion Inc. in November 2010. Nordion Inc. was founded in 1946 and is headquartered in Ottawa, Canada.

Technical Indicators should be used as the starting point for further analysis. These indicators are provided as a guide to help you determine what assets to analyze. The technical indicators used in this article can indicate that an asset is either overbought or oversold, but that indication could be the result of a fundamental or other type of event like an earnings announcement.

To learn more about technical analysis, please refer to our technical analysis primer.